Why Strong Science Is Not Enough

How Life Sciences Investors Really Evaluate Your Startup

A live session for life sciences founders who want to understand why solid data and publications are not getting investor traction and what to change in their story, materials, and process so serious investors can actually say yes.

Date: December 18, 2025
Time: 12:00 PM EST
Duration: 60 minutes live with Q&A

Register for the Live Session

Reserve your seat for this sixty minute session. Designed for scientific founders in life sciences.

Who This Session Is For

This session is designed for scientific leaders who are navigating the complex intersection of groundbreaking research and investment readiness. Whether you're building the next breakthrough therapy or developing innovative diagnostic tools, understanding investor expectations is critical to your success.

This session serves:

  • Scientific founders and chief executives in therapeutics, medical devices, diagnostics, biotech services, and healthcare information technology
  • Pre-seed and seed teams who expect to raise from angels or first institutional life sciences funds in the next twelve to eighteen months
  • Venture-backed teams preparing for the next institutional or strategic round who want a clearer view of how their venture is seen from the investor and acquirer side

If you have strong science but feel unsure about what investors really expect from your materials and story, this session is for you.

Why Strong Science Is Not Enough

Most scientific founders do not fail because the science is weak. The data is compelling, the publications are in top-tier journals, and the research team has impeccable credentials. Yet somehow, investor conversations that start with enthusiasm quietly fade away without clear explanation.

The Opaque Path

The journey from interesting data to an investable venture remains unclear, leaving founders uncertain about what investors actually need to see

Science Without Strategy

Founders talk extensively about the science but rarely address the development pathway, commercialization strategy, and realistic exit scenarios

Materials That Create Work

Decks and summaries make investors work too hard to understand the real bet, the key milestones, and the capital efficiency of the plan

Silent Credibility Damage

Early missteps in outreach and due diligence quietly damage credibility without anyone saying so directly, closing doors before you realize it

Investors and acquirers are evaluating your evidence, your Target Product Profile, and your plan through a very specific lens. When you do not see what they see, promising conversations fade away. This session will show you that lens and help you understand exactly what needs to change.

What You Will Learn in This Session

This is not another generic pitch workshop. You will gain specific, actionable insights into how life sciences investors and strategic acquirers actually evaluate early-stage opportunities, and you will learn exactly what to fix in your own materials before your next funding conversation.

01

How life sciences investors and acquirers really look at your startup

You will see the basic mental model investors and acquirers use to assess risk and potential across science, clinical pathway, regulatory strategy, reimbursement, and market fit. Understanding this framework will transform how you position your venture.

02

The quiet red flags that kill interest before due diligence

You will learn the most common early signals in your deck, summary, and conversations that tell serious investors you are not yet ready, even when the data looks promising. These subtle missteps cost you meetings and credibility.

03

How to connect your data, TPP, and capital ask into one coherent story

You will see how to link your Target Product Profile, current evidence, development plan, and use of funds into an investor-ready narrative that partners can carry into their internal meetings with confidence.

04

What to fix first in your own materials

You will leave with a simple diagnostic and a recommended order of work so you know what to improve in your current summary, pitch, and data room before your next raise. No more guessing about priorities.

Meet Your Session Leader

Jim Jordan

Learn from someone who has been the buyer, the seller, and the investor in life sciences deals.

Jim Jordan has served as a senior executive in Fortune 100 healthcare companies with profit and loss responsibility and a mandate to grow through partnerships and acquisitions. He has also been a senior leader in multiple venture-backed startups, helping prepare companies for sale and working directly with bankers and acquirers through diligence and negotiation.

As Chief Investment Officer and then Chief Executive Officer of Pittsburgh Life Sciences Greenhouse from 2005 to 2020, he worked with 483 life sciences companies across therapeutics, devices, diagnostics, biotech, and health technology. He directed $60 million to university investments and $25 million into one hundred 135 startups, overseeing a portfolio that went on to generate more than $1.5 billion in regional equity and about $600 million in investor returns through 11 exits, led by the companies' management teams.

Today he acts as a commercialization and capital strategy coach for life sciences executives, serves as co-chairman of a life sciences pre-seed bootcamp, advises on accelerator curricula, and has designed and led graduate and executive programs in life sciences commercialization, healthcare, and healthcare data analytics. He is the author of two books on startups and one on strategic patents, curates HealthcareData.Center, and hosts the ChalkTalkJim podcast on real world healthcare innovation.

How the Session Runs

This is a focused sixty-minute live session designed to give you maximum value in minimum time. You will not sit through endless slides or generic startup advice. Every minute is designed to help you see your venture more clearly through an investor lens.

Opening Context

A short overview of why strong science is not enough and how investors and acquirers frame early opportunities in life sciences

Core Teaching

A walkthrough of the key lenses investors use, the common early red flags, and how TPPs, evidence, and capital plans fit together

Real Application

Examples of how different types of life sciences ventures can adjust their story and materials using the same principles

Live Questions

Time for participant questions on investor expectations, materials, and your specific next steps

You will also receive a simple one-page diagnostic you can use after the session to review your own summary and deck. This tool alone is worth attending for, as it will give you a systematic way to evaluate your materials against investor expectations.

What You Will Be Able to Do Differently

The real measure of this session is not what you learn, but what you will be able to do differently when you walk into your next investor conversation or update your pitch materials. These outcomes are specific, measurable, and immediately applicable to your fundraising process.

See Through Investor Eyes

View your venture more clearly through an investor and acquirer lens, understanding exactly how your story, data, and plan will be evaluated against their internal criteria

Eliminate Red Flags

Know the most important early red flags to remove from your materials and conversations before they silently close doors you did not know were closing

Improve Your Materials

Have a simple checklist to improve your summary, pitch, and data room before your next raise, with clear priorities on what to fix first

Gain Confidence

Feel more confident that you understand what serious investors are looking for and why, reducing the guesswork and anxiety of fundraising

These are not abstract benefits. They translate directly into better investor conversations, stronger materials, and a higher probability of closing the capital you need to advance your science into the clinic and the market.

What Happens After the Webinar

If you find the session valuable and want help applying these ideas in a structured way, you will also hear how Jim works with founders through the Life Sciences Capital Readiness Program. This is a focused coaching engagement designed specifically for scientific founders who want to transform their story, materials, and investor conversations from adequate to exceptional.

There will be an optional invitation at the end of the session to book a short Capital Readiness Call to talk about your specific situation. The webinar itself is focused on teaching, not a long sales pitch. You will leave with value whether or not you choose to explore additional support.

The goal is simple: help you understand what investors and acquirers are really looking for so you can make informed decisions about how to position your venture and when to reach out for deeper engagement.

Frequently Asked Questions

Who should attend?

Scientific founders and chief executives of life sciences ventures in therapeutics, medical devices, diagnostics, biotech services, or healthcare information technology who expect to raise capital in the next one to three years. Both pre-seed and seed teams and venture-backed teams preparing for the next institutional or strategic round are welcome.

Will the session be recorded?

Yes. If you register and cannot attend live, you will receive a recording of the main teaching segment and the slides. However, live attendance is strongly encouraged so you can ask questions specific to your situation.

Is this a sales pitch for a paid program?

The focus of the session is on teaching you how investors and acquirers actually evaluate life sciences ventures and how to improve your story and materials. At the end, Jim will briefly explain how the Life Sciences Capital Readiness Program works for founders who want to go deeper. There is no obligation to take any next step.

What does it cost?

There is no fee for this session. The ask is that you attend with a specific venture in mind and be ready to reflect honestly on how investors and acquirers may currently be seeing it. Come prepared to think critically about your current materials and story.

Your Next Move

Strong science deserves strong positioning. If your data is solid but investor conversations are not converting, the problem is rarely the science. It is usually how you are framing the opportunity, what you are leaving out of your story, or how you are showing up in early interactions.

This sixty-minute session will give you the clarity you need to see your venture through investor eyes and make the specific improvements that will change how serious capital partners respond to your outreach. Do not let another quarter go by wondering why strong science is not translating into investor traction.

Join the live session and see your venture through an investor lens before your next raise.